T-Therapeutics I Platform
Our proprietary suite of best-in-class platform technologies is foundational to our bispecific TCR-CD3 T cell engagers
Platform I TCR-CD3-Fc
Platform I OpTiMus®
Best-in-class platform unlocking targeting of disease self-antigens
We engineer soluble TCRs that bind with high affinity and exquisite specificity to disease specific targets. Our proprietary OpTiMus® platform, provides an unparalleled supply of fully human TCRs, enabling us to select for those with the required properties.
Applying yeast display, combined with machine learning and in silico structural prediction, we identify highly specific and high affinity molecules, minimising off-target binding from the outset and providing robust building blocks for therapeutics with potential across multiple disease indications.
Modularity I T-Bridge®
Optimum modular design for potency and safety
Advances in the structural understanding of how T cells kill has instructed the development of our T-Bridge® format. This modular backbone combines our engineered TCRs and CD3 binder with an Fc region in an exquisitely optimised geometry for T cell engagement. This allows for extended half-life compatible with conventional dosing schedules while enabling targeting of low density targets.
CD3 binders for optimal T cell recruitment and activity
Our proprietary, next generation CD3 binders recruit T cells to target cancer cells or pathogenic immune cells.
These fully human CD3 molecules have been tuned to potently kill the target cell, whilst minimising cytokine release which drives many of the side effects of existing T cell engagers. Our CD3 molecules have also been engineered for favourable pharmacokinetics to drive durable efficacy.
Pipeline
T-Therapeutics
One Granta
Granta Park
Cambridge
CB21 6DP